Progress of triazole antifungal agent posaconazole in individualized therapy
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.13821
Abstract: Posaconazole is the second‐generation triazole antifungal agent with widespread clinical application. Posaconazole exposure is influenced by various factors such as drug interactions, disease state and diet, resulting in a high interindividual variability in many patients… read more here.
Keywords: triazole antifungal; individualized therapy; antifungal agent; posaconazole ... See more keywords
The Influence of Different Triazole Antifungal Agents on the Pharmacokinetics of Cyclophosphamide
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Pharmacotherapy"
DOI: 10.1177/1060028019896894
Abstract: Background: Cyclophosphamide is one of the most important chemotherapeutic drugs. Known as a widely accepted treatment strategy, chemotherapy may damage the immune function of cancer patients; as a result, invasive fungal infections (IFIs) occur. Triazole… read more here.
Keywords: antifungal agents; ketoconazole; triazole antifungal; pharmacokinetics cyclophosphamide ... See more keywords
Use of modeling and simulation to predict the influence of triazole antifungal agents on the pharmacokinetics of zanubrutinib and acalabrutinib
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.960186
Abstract: Background: Bruton’s tyrosine kinase (BTK) inhibitors are commonly used in the targeted therapy of B-cell malignancies. It is reported that myelosuppression and fungal infections might occur during antitumor therapy of BTK inhibitors, therefore a combination… read more here.
Keywords: triazole antifungal; influence; predict; zanubrutinib acalabrutinib ... See more keywords